The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”) is currently proposing a non-public offering of shares. Due to the uncertainty of the matter, in order to ensure fair information disclosure, safeguard the interests of investors, and avoid significant impact on the company's stock price, according to the Stock Exchange Listing Rules of the Shenzhen Stock Exchange and the “Guidelines for the Standardized Operation of Listed Companies of SME Boards” Relevant regulations, after the company applied to the Shenzhen Stock Exchange, the company's stock (stock short name: Zixin Pharmaceutical, stock code: 002118) has been suspended since the market opened on August 21, 2014.
The company's stock will be reviewed after the company's board of directors deliberated and passed the relevant proposal on the matter and disclosed it. Investors are advised to pay attention to relevant announcements and pay attention to investment risks.
Jilin Zixin Pharmaceutical Co., Ltd.
Board of Directors
August 21, 2014